Project Grant R01AI177997
Award Date
8/12/24
Completion Date
7/31/29
Dollars Obligated
$714K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14214, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $112,077 to The Ohio State University to develop novel bacteriophage-based therapies to combat Pseudomonas aeruginosa and Candida spp. dual-species biofilms. The project aims to generate combination treatments utilizing antimicrobial peptides and genetically engineered bacteriophages to target these polymicrobial...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel assay for targeted isolation of bacteriophages (phages) from environmental samples. The $173,030 award will be used to create a co-culture-based technique that can differentiate phages based on their infection dependencies, allowing for the preferential selection of phages that require specific...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Phagepro, Inc., a minority-owned and woman-owned small business, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This 3-year grant, with a project period from December 16, 2024, to May 31, 2027, supports the development of a prophylactic cholera phage cocktail. Phagepro, which specializes in bacteriophage-based solutions for infectious disease prevention and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of self-recirculating, non-replicating bacteriophage (phage) vectors as a platform for targeted gene therapy of the human microbiome. The $233,250 award, effective from May 13, 2025 to April 30, 2027, aims to produce and characterize various self-contained non-replicative phage vectors (SCNRPVs) and...
This federal Project Grant award, provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286), aims to develop an adaptive framework to rapidly synthesize and reconfigure synthetic bacteriophages (phages) to counter antibiotic-resistant pathogens. The $128,461 award will fund research to optimize an E. coli cell-free system to produce phages...
This federal Project Grant award, totaling $195,625.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to structurally and functionally characterize phosphoethanolamine (PEtN) transferases, which are enzymes responsible for conferring resistance to cationic antimicrobial peptides and polymyxin antibiotics in certain Gram-negative bacteria. The research aims...
This $779,915 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by the Scripps Research Institute to investigate the chromatin remodeling functions of polyphosphate condensates in the bacterial pathogen Pseudomonas aeruginosa. The project aims to define the relationship between polyphosphate and the DNA-binding protein AlgP in regulating gene expression and...
This $2,308,174 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop new antibiotic combinations and dosing strategies to combat carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The award, which runs from August 8, 2024 to May 31, 2029, involves three projects and three cores conducted by the University of Florida, the...
This Project Grant award, totaling $237,518, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research aims to identify synergistic combinations of aminoglycoside antibiotics that can effectively treat multidrug-resistant Gram-negative bacterial infections while also suppressing the emergence of resistance and limiting toxicity. Key objectives include: 1) Screening diverse...
This Project Grant award of $453,621.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to understand how changes in the lipopolysaccharide (LPS) composition of the bacterial pathogen Pseudomonas aeruginosa (PA) influence aggregate formation and social behaviors in chronic cystic fibrosis lung infections. The key products and services to be delivered include: (1) determining the frequency of PA...